Stockscreener 앱 받기
6.40
4.05%
-0.27
시간 외 거래:
6.38
-0.02
-0.31%
전일 마감가:
$6.67
열려 있는:
$6.75
하루 거래량:
250.95K
Relative Volume:
2.61
시가총액:
$124.41M
수익:
-
순이익/손실:
$-22.38M
주가수익비율:
-4.129
EPS:
-1.55
순현금흐름:
$-15.54M
1주 성능:
-6.57%
1개월 성능:
+1.91%
6개월 성능:
-41.82%
1년 성능:
-56.10%
1일 변동 폭
$6.0001
$7.04
1주일 범위:
$6.0001
$7.04
52주 변동 폭
$5.85
$14.96
Nuvectis Pharma Inc Stock (NVCT) Company Profile
명칭
Nuvectis Pharma Inc
전화
360-837-7232
주소
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-07-13 | 개시 | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc 주식(NVCT)의 최신 뉴스
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch - StockTitan
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Down 8.5% - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Trading Down 8.5% - Defense World
Nuvectis’ NXP800 gains FDA ODD for cancer treatment - MSN
Insider Buyers Lose Additional US$46k As Nuvectis Pharma Dips To US$115m - Simply Wall St
When (NVCT) Moves Investors should Listen - Stock Traders Daily
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Nuvectis Pharma Inc (NVCT) Becoming More Attractive for Investors - Knox Daily
Is Nuvectis Pharma Inc (NVCT) worth investing in despite its overvalued state? - US Post News
The time has not yet come to remove your chips from the table: Nuvectis Pharma Inc (NVCT) - SETE News
Nuvectis Pharma gets FDA Orphan Drug Designation for NXP800 - World Pharmaceutical Frontiers
Nuvectis’ NXP800 gains FDA ODD for cancer treatment - Yahoo Finance
Nuvectis’ NXP800 gains FDA ODD for cancer treatment - Pharmaceutical Technology
Nuvectis Pharma receives FDA orphan drug status for cancer treatment - Investing.com India
Nuvectis Pharma Announces Orphan Drug Designation Granted - GlobeNewswire
Nuvectis Pharma Secures FDA Orphan Drug Designation for NXP800, Advancing Treatment for Rare Ovarian Cancers - Vancity Buzz
Precision Medicine Trailblazer Nuvectis Pharma Secures FDA Orphan Drug Designation for NXP800 - Markets Herald
Nuvectis stock gains on FDA’s orphan status (NASDAQ:NVCT) - Seeking Alpha
Nuvectis Shares Rally After Ovarian Cancer Drug Gets FDA's Orphan Drug Designation - MarketWatch
Nuvectis Pharma receives FDA orphan drug status for cancer treatment - Investing.com
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers - StockTitan
Positive Signs As Multiple Insiders Buy Nuvectis Pharma Stock - Yahoo Finance
Recent Insider Activity Could Benefit Nuvectis Pharma Inc (NVCT) - Knox Daily
Vanguard Group Inc. Has $2.45 Million Holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
How the (NVCT) price action is used to our Advantage - Stock Traders Daily
Approaching Potentially Game-Changing Clinical Data: - openPR
Approaching Potentially Game-Changing Clinical Data: Nuvectis Pharma Reported Strong Q2 2024 Results (NASDAQ: NVCT) - Barchart
Approaching Potentially Game-Changing Clinical Data: Nuvectis Pharma Reported Strong Q2 2024 Results (NASDAQ: NVCT) | FinancialContent Business Page - Financial Content
Nuvectis Pharma, Inc. to Post Q3 2024 Earnings of ($0.26) Per Share, HC Wainwright Forecasts (NASDAQ:NVCT) - MarketBeat
Q3 2024 EPS Estimates for Nuvectis Pharma, Inc. Increased by HC Wainwright (NASDAQ:NVCT) - Defense World
Nuvectis Pharma, Inc. Forecasted to Earn Q3 2024 Earnings of ($0.25) Per Share (NASDAQ:NVCT) - Defense World
Nuvectis Pharma’s (NVCT) Buy Rating Reaffirmed at HC Wainwright - Defense World
Nuvectis Pharma (NASDAQ:NVCT) Rating Reiterated by HC Wainwright - MarketBeat
Nuvectis Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights - StockTitan
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights - Yahoo Finance
Recent 11% decline may not have gone down well with Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders who've been purchasing recently - Simply Wall St
(NVCT) Investment Analysis - Stock Traders Daily
5 Reasons Why Nuvectis Pharma (NASDAQ: NVCT) Is a Biopharma Innovator to Watch - Market Research Record
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Short Interest Down 18.1% in July - MarketBeat
Insiders hold 65% of Nuvectis Pharma, Inc. (NASDAQ:NVCT), and they've been buying recently - Yahoo Finance
Long Term Trading Analysis for (NVCT) - Stock Traders Daily
Reviewing Nuvectis Pharma (NASDAQ:NVCT) and NanoViricides (NYSE:NNVC) - Defense World
Nuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine Market - openPR
Nuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine Market - The Globe and Mail
Nuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine Market - Barchart
Market Momentum Report: Nuvectis Pharma Inc (NVCT)'s Negative Close at 6.20 – DWinneX - The Dwinnex
NVCT Stock Sees Decline of Approximately -4.62% in Last Five Days – Knox Daily - Knox Daily
Nuvectis Pharma Inc (NVCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Nuvectis Pharma Inc 주식 (NVCT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BENTSUR RON | Chairman & CEO |
May 10 '24 |
Buy |
6.40 |
2,000 |
12,800 |
3,244,484 |
| Poradosu Enrique | Chief Science & Business Off |
May 10 '24 |
Buy |
6.29 |
500 |
3,145 |
1,504,319 |
| Shemesh Shay | Chief Dev. & Ops. Officer |
May 10 '24 |
Buy |
6.32 |
1,113 |
7,034 |
1,493,068 |
| BENTSUR RON | Chairman & CEO |
Mar 18 '24 |
Buy |
10.29 |
5,000 |
51,450 |
3,242,484 |
| BENTSUR RON | Chairman & CEO |
Oct 10 '23 |
Buy |
11.08 |
640 |
7,091 |
3,237,484 |
| BENTSUR RON | Chairman & CEO |
Oct 09 '23 |
Buy |
11.19 |
830 |
9,288 |
3,236,844 |
| BENTSUR RON | Chairman & CEO |
Oct 06 '23 |
Buy |
11.27 |
250 |
2,818 |
3,236,014 |
| BENTSUR RON | Chairman & CEO |
Oct 04 '23 |
Buy |
10.95 |
1,820 |
19,929 |
3,234,364 |
| BENTSUR RON | Chairman & CEO |
Oct 05 '23 |
Buy |
11.09 |
1,400 |
15,526 |
3,235,764 |
1.10%
1.27%
자본화:
|
볼륨(24시간):